Request Demo

Last update 09 Mar 2026

Vericiguat

Last update 09 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

维利西呱, BAY 102, BAY 1021189

+ [8]

Target

sGC

Action

stimulants

Mechanism

sGC stimulants(Soluble guanylate cyclase stimulants)

Therapeutic Areas

Cardiovascular DiseasesOther DiseasesNeoplasms+ [6]

Active Indication

Reduced ejection fraction co-occurrent and due to chronic heart failureChronic heart failureHeart Failure+ [15]

Inactive Indication

Angina, StableHeart failure with normal ejection fraction

Originator Organization

Bayer AG

Active Organization

Merck Sharp & Dohme LLC

MSD R&D (China) Co. Ltd.

Merck Sharp & Dohme Corp.

+ [4]

Inactive Organization

Merck & Co., Inc.

Bayer Pharma AG

Bayer HealthCare AG

License Organization

Dr. Reddy's Laboratories Ltd.Bayer Korea Ltd.

Merck & Co., Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (19 Jan 2021),

Heart FailureShock

RegulationPriority Review (China), Conditional marketing approval (China), Special Review Project (China), Fast Track (United States)

Structure/Sequence

Molecular FormulaC19H16F2N8O2

InChIKeyQZFHIXARHDBPBY-UHFFFAOYSA-N

CAS Registry1350653-20-1

Clinical Trials associated with Vericiguat

NCT06320951

/ Not yet recruitingPhase 2IIT

Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.

Start Date01 Dec 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

ChiCTR2600119938

/ Not yet recruitingPhase 4IIT

Tolerability and Safety of Vericiguat Initiation at 10 mg vs 5 mg in Patients with HFrEF and SBP>=130 mmHg:A Phase IV Randomized Trial

Start Date15 Feb 2026

Sponsor / Collaborator

The First Hospital of Jilin University

ChiCTR2600119767

/ Not yet recruitingPhase 4IIT

Study on the Efficacy and Safety of Vericiguat in Patients with Acute Myocardial Infarction Combined with Mildly Reduced Ejection Fraction (LVEF: 45–50%)

Start Date05 Feb 2026

Sponsor / Collaborator

The First Hospital of Jilin University

100 Clinical Results associated with Vericiguat

100 Translational Medicine associated with Vericiguat

100 Patents (Medical) associated with Vericiguat

345

Literatures (Medical) associated with Vericiguat

01 May 2026·Value in Health Regional Issues

Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction

Article

Author: Krittayaphong, Rungroj ; Kongmalai, Tanawan ; Jirataiporn, Kanchalaporn

OBJECTIVES:

This study aimed to evaluate the cost-utility of adding vericiguat to standard-of-care therapy for patients with heart failure with reduced ejection fraction (HFrEF) and worsening heart failure (HF) events in the context of Thailand's healthcare system.

METHODS:

A Markov model using Microsoft Excel was conducted to simulate the lifetime economic outcomes of adding vericiguat to standard-of-care therapy (SoCT) compared with SoCT alone for Thai patients with HFrEF. Model parameters were derived from the VICTORIA trial and supplemented with local data on healthcare costs and utilities. Sensitivity, subgroup, and threshold analyses were also performed.

RESULTS:

Adding vericiguat to SoCT increased total life-years (LYs) from 5.80 to 5.98 and quality-adjusted life-years (QALYs) from 2.74 to 2.85. However, it also increased total lifetime costs by 114 740 THB ($3114) per patient compared with SoCT alone, resulting in an incremental cost-effectiveness ratio of 1 063 375 THB ($28 857) per QALY gained. Subgroup analysis based on NT-proBNP levels demonstrated that vericiguat had a more favorable incremental cost-effectiveness ratio of 557 427 THB ($15 127) per QALY gained in patients with NT-proBNP ≤ 4000 pg/mL. Considering the current willingness-to-pay threshold of 160 000 THB ($4342) per QALY gained in Thailand, vericiguat did not meet the cost-effectiveness criteria.

CONCLUSIONS:

Despite its clinical benefits in reducing HF hospitalizations and cardiovascular mortality, vericiguat as an adjunct to SoCT for patients with HFrEF in Thailand exceeds the accepted cost-effectiveness threshold of 4342 USD/QALY gained. A price reduction of 90.2% would be necessary to achieve the current Thai willingness-to-pay threshold.

01 Feb 2026·AMERICAN HEART JOURNAL

Vericiguat and hypotension in patients with heart failure and reduced ejection fraction: VERIFY-HF registry

Article

Author: Fukumoto, Katsunori ; Watanabe, Yukihiro ; Morinaga, Takashi ; Kaneko, Tomohiro ; Okabe, Kota ; Matsumura, Koichiro ; Goto, Reiji ; Fujimoto, Wataru ; Oka, Yosuke ; Onishi, Tomohiro ; Takigami, Yu ; Arai, Keiko ; Suzuki, Daiki ; Takase, Toru ; Shibata, Atsushi ; Takegawa, Koki ; Shibata, Tatsuhiro ; Takuwa, Junna ; Kanaoka, Koshiro ; Sakamoto, Akira ; Nakazawa, Gaku ; Nakamura, Keijiro ; Nakano, Yusuke ; Kikuchi, Atsushi ; Ishihara, Satomi ; Amano, Tetsuya ; Kida, Keisuke ; Matsukawa, Ryuichi ; Kubota, Yoshiaki ; Ikeda, Takanori ; Shiraishi, Yasuyuki ; Takigahira, Takuya ; Ishii, Shunsuke ; Matsuzoe, Hiroki ; Kagiyama, Nobuyuki ; Shibao, Kodai ; Yanai, Toshiyuki ; Ijichi, Takeshi ; Ono, Ryohei ; Miyahara, Daisuke ; Matsumoto, Shingo ; Nohara, Shoichiro ; Akagaki, Daiki ; Ikegami, Shogo ; Kitai, Takeshi ; Nakaoji, Takashi ; Hayama, Hiromasa ; Saito, Yu ; Ikeda, Kazuya ; Iida, Yuichiro ; Nasu, Takahito ; Arai, Riku ; Yazaki, Yoshiyuki ; Kanenawa, Kenji

BACKGROUND:

Real-world characteristics and outcomes in patients with heart failure (HF) and reduced ejection fraction (HFrEF) treated with vericiguat remain unclear. We investigated patient characteristics, hypotension-the most relevant clinical event-, and outcomes after initiating vericiguat in patients with HFrEF.

METHODS:

In this nationwide, multicentre retrospective study involving 22 hospitals in Japan, we examined symptomatic or asymptomatic hypotension and drug discontinuation within 90 days after initiation of vericiguat in patients with left ventricular ejection fraction <45%. The association between hypotension and HF outcomes was also examined.

RESULTS:

Among the 799 patients with HFrEF, the mean age was 69.6 years, and 218 (27.3%) were female. Of them, 316 (39.5%) had New York Heart Association classification III or IV, and 329 (41.8%) had systolic blood pressure (sBP) <100 mm Hg. Hypotension was observed in 25.3% of patients within 90 days, with asymptomatic hypotension being the most common (17.9%). By contrast, drug discontinuation related to hypotension was less frequent (4.4%). After adjustment, sBP <100 mm Hg, low body mass index, and in-hospital vericiguat initiation were associated with the incidence of hypotension within 90 days. Patients who experienced hypotension had a greater risk of cardiovascular death or HF hospitalization than those who did not (P = .01).

CONCLUSIONS:

Although hypotension was relatively common soon after starting vericiguat, they were not often associated with drug discontinuation. Patients experiencing hypotension had a greater risk of HF outcomes, but this would be primarily associated with their vulnerability, given the infrequent discontinuation.

01 Feb 2026·American heart journal plus : cardiology research and practice

Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice

Article

Author: Lecomte, Coralie ; Holl, Katsiaryna ; Michel, Alexander ; Manca, Paolo ; Senni, Michele ; Greene, Stephen J

Study objective:

To evaluate the following among new users of vericiguat: up-titration patterns, factors associated with up-titration, occurrence of hypotension/syncope, predictors of hypotension/syncope.

Design:

Retrospective cohort study (linked claims and electronic health record data).

Setting:

US clinical practice.

Participants:

1361 new users of vericiguat.

Interventions:

N/A.

Main outcome measures:

Vericiguat starting dose, up-titration patterns and predictors, occurrence and predictors of hypotension/syncope, over a 3-month follow-up period.

Results:

Among 1361 new users of vericiguat, 770 (57%) initiated a starting dose of 2.5 mg/day, 330 (24%) initiated a dose of 5 mg/day, and 261 (19%) initiated a dose of 10 mg/day. Over 3-month follow-up, the 10 mg target dose was reached by 349 (26%) patients. Among these patients, the median time to reach the 10 mg dose was 60 days among 2.5 mg/day starters, and 41 days among 5 mg/day starters. Among the 2.5 mg starters, 68% had no up-titration. Among patients initiating either the 2.5 mg/day or 5 mg/day dose, a starting dose of 5 mg (vs. 2.5 mg) was the only significant predictor for reaching the 10 mg dose; adjusted hazard ratio 2.89 (95% CI: 1.86, 4.49, p < 0.0001). Overall, 130 patients (9.6%) had a hypotension event and 67 patients (4.9%) had a syncope event. History of hypotension was the strongest independent predictor of hypotension/syncope events (adj. HR 2.85, 95% CI: 1.96, 4.13, p < 0.0001). A > 2.5 mg/day vericiguat starting dose was not associated with the occurrence of hypotension/syncope (vs. 2.5 mg/day); adj. HR 0.82, 95% C.I. (0.58, 1.16).

Conclusion:

Vericiguat users initiated on the 5 mg/day dose were considerably more likely to reach the target dose of 10 mg/day vs. those started on the recommended 2.5 mg/day dose, without excess risk of hypotension or syncope.

News (Medical) associated with Vericiguat

04 Sep 2025

·www.prnewswire.com

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 26-29

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN. Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Continue Reading Heart Failure Society of America Annual Scientific Meeting 2025 takes place September 26-29 in Minneapolis, MN. Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 1: Devices and Cardiomyopathies Integra-D Trial Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial FUTURE-HF Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio DETECT-HF Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days FOREST-HCM Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: a 96-week analysis from FOREST-HCM MAPLE-HCM Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM ATTRibute-CM Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM HELIOS-B Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 2: Novel Therapies VICTOR Trial Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients with HFrEF Enrolled in the VICTOR trial Tolerability and Safety of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction SEISMiC C Safety and Efficacy of Intravenous Administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to Acute Heart Failure SUMMIT Trial Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial GARDEN TIMI-74 GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial Danicamtiv Trial Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network First-In-Human Implantation of a Next-Generation Membrane-Based LVAD Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis Screening for advanced heart failure in stable outpatients (The SAINTS study) Sunday, September 28 | Rapid Fire 2: | 2:15 PM - 3:15 PM Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial Expanded Results from a Guideline-Directed Medical Therapy Clinic Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset PROACTIVE-HF: 2-year outcomes, stratified by LVEF Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2025. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected] SOURCE Heart Failure Society of America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Phase 1

02 Sep 2025

·www.fiercepharma.com

Merck, Bayer's Verquvo posts perplexing trial fail in patients with stable HFrEF

Analysts don't hold big expectations for Verquvo because of competition in the heart failure field. Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF).The phase 3 Victor trial failed on its primary endpoint, as Verquvo didn’t beat placebo in terms of combined time to first heart failure hospitalization or cardiovascular death, according to results presented at the European Society of Cardiology Congress 2025. The study evaluated Verquvo in more than 6,100 well-managed HFrEF patients who had not had a heart failure hospitalization within six months or the need for outpatient intravenous diuretics within three months prior to the study. About 47.5% of patients had no history of hospitalization for heart failure.The readout was perplexing because investigators observed seemingly divergent results on the two components that formed the trial’s primary composite endpoint.Verquvo led to a numerical 17% reduction in the risk of heart-related death. The number did not bear statistical significance because secondary endpoints were not formally tested thanks to the trial’s failure on its primary endpoint.Death from cardiovascular causes occurred in 292 (9.6%) patients in the Verquvo arm and 346 (11.3%) in the control group after a median follow-up of 19.7 months, according to results simultaneously published in The Lancet.In contrast, the drug showed no sign of benefit on time to first heart failure hospitalization, with Verquvor’s 11.4% first-time hospitalization rate during the study timeframe looking similar to placebo’s 11.9%. When first and recurrent hospitalizations were counted, Verquvo’s rate was 10.7 events per 100 patient-years versus 11.8 events per 100 patient-years for the placebo cohort.“Cardiovascular death is a clinically meaningful and less ambiguous endpoint than outcomes such as hospitalization, which can be influenced by clinical practice and regional variation,” the Victor trial’s investigators wrote in The Lancet paper.Trying to reconcile the difference between the two endpoints, the researchers pointed to “the unprecedented high use of guideline-directed medical therapy,” such as SGLT2 inhibitors, in a population with overall low risk at baseline. Even though the researchers hypothesized that the high use of contemporary therapy and low recent hospitalization rates could offer plausible explanations for the lack of a hospitalization benefit, they acknowledged that “[t]he reason for the observed mortality benefit in the absence of a reduction in heart failure hospitalization is unclear.”All told, on the composite endpoint, Verquvo only led to a nonsignificant 7% reduction in the risk of cardiovascular death or first hospitalization for heart failure during a median follow-up of 18.5 months.Verquvo received its initial FDA approval in HFrEF in 2021 based on results from the phase 3 Victoria trial. The study linked the soluble guanylate cyclase stimulator to a reduced risk of cardiovascular death and heart failure hospitalization versus placebo among patients with worsening disease. At ESC, Merck also trotted out a pooled analysis of Victor and Victoria, showing that Verquvo significantly reduced patients’ risk of cardiovascular mortality or heart failure hospitalization by 9% versus placebo. The risk reduction was 11% and 8% for the marker’s two components, respectively.Through a collaboration formed in 2014, Merck markets Verquvo in the U.S. and Bayer commercializes it in the rest of the world.Analysts don't hold big expectations for Verquvo because of competition in the heart failure field. At the time of the drug’s approval in 2021, Leerink Partners analysts projected its U.S. peak sales would reach $300 million based on some use in HFrEF patients who are not optimally managed on Novartis’ Entresto.In the first half of 2025, Merck only recorded $21 million in sales from the med in the U.S.

Phase 3Drug ApprovalClinical ResultAHA

02 Sep 2025

·endpoints.news

Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager

Plus, news about Zenas BioPharma, OMass Therapeutics, Merck, Bayer, Convalife Pharmaceuticals, Mabwell Bioscience, CapVest, Stada and vTv Therapeutics: 💰 Servier licenses Ideaya Biosciences’ cancer drug: The French pharma is getting the ex-US rights to Ideaya’s experimental uveal melanoma drug for $200 million upfront. Servier could fork over another $320 million in biobucks for the Phase 2/3 candidate, which is named darovasertib. — Kyle LaHucik 🧪 Zymeworks discontinues work on T cell engager: The biotech determined that its additional dose evaluation in a Phase 1 trial of ZW171 wouldn’t yield the benefit-risk profile it wanted. Zymeworks had planned to test the TCE in cancers with high levels of mesothelin. — Jaimy Lee 🧾 Zenas BioPharma makes a royalty deal: Royalty Pharma is paying $75 million upfront and up to $300 million total in exchange for the royalties on sales of obexelimab, Zenas’ experimental bifunctional monoclonal antibody that’s being tested in several autoimmune diseases. An increasing number of biotechs are inking royalty deals to bolster their balance sheets. — Jaimy Lee 🇨🇭 OMass Therapeutics, Roche ink deal: The Swiss drugmaker is paying $20 million upfront for the rights to develop and commercialize OMass’ preclinical oral inflammatory bowel disease program. There are also more than $400 million in milestones and tiered royalties on the table. — Jaimy Lee 🫀 Merck and Bayer’s Verquvo fails a Phase 3 study in heart failure: The companies have been testing the drug in adults with stable chronic heart failure and reduced ejection fraction. Verquvo is already approved to treat a different subset of patients with heart failure. — Jaimy Lee 🇨🇳 Two Chinese biotechs file for IPOs in Hong Kong: This includes Convalife Pharmaceuticals , a decade-old cancer drug developer with one approved medicine and 16 others in development, and Mabwell Bioscience , a cancer and age-related diseases biotech founded eight years ago. Mabwell is already listed on the Shanghai Stock Exchange STAR Market. It tried for an HKEX listing in January but let its filing lapse. The companies are the latest to file to go public in the still active IPO market in Hong Kong. — Kyle LaHucik 🇩🇪 CapVest Partners takes a majority stake in Stada: Sources told The Financial Times that Stada has a valuation of roughly €10 billion, including debt. Bain Capital and Cinven acquired Stada in 2017 and then took the German pharma company private. Stada was known as a generics maker but has since broadened its business into consumer healthcare and specialty drugs. The deal is expected to close in the first half of next year — Jaimy Lee 💊 vTv Therapeutics’ $80M private placement: The company plans to use the funding to advance cadisegliatin, its Phase 3 adjunctive therapy to insulin for patients with type 1 diabetes. The PIPE’s investors include several institutional investors and the T1D Fund. — Jaimy Lee

Phase 1AcquisitionDrug ApprovalPhase 3License out/in

100 Deals associated with Vericiguat

External Link

KEGG	Wiki	ATC	Drug Bank
D11051	Vericiguat	C01DX	DB15456

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Reduced ejection fraction co-occurrent and due to chronic heart failure	China	Bayer AG	18 May 2022
Chronic heart failure	European Union	Bayer AG	16 Jul 2021
Chronic heart failure	Iceland	Bayer AG	16 Jul 2021
Chronic heart failure	Liechtenstein	Bayer AG	16 Jul 2021
Chronic heart failure	Norway	Bayer AG	16 Jul 2021
Heart Failure	United States	Merck Sharp & Dohme LLC	19 Jan 2021
Shock	United States	Merck Sharp & Dohme LLC	19 Jan 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic systolic heart failure	Phase 3	United States	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Belgium	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Brazil	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Canada	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Colombia	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Croatia	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Denmark	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Finland	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	France	Merck Sharp & Dohme LLC	23 Mar 2023
Chronic systolic heart failure	Phase 3	Germany	Merck Sharp & Dohme LLC	23 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05711719 (CTgov)	Phase 2	Metabolic Syndrome \| Coronary microvascular dysfunction \| Anomalous Left Coronary Artery	45	Vericiguat (Vericiguat)	ivdjpbmlch(xkmzovymnl) = drwbyjymis hxijamkdip (mtlqdjaxkx, 1.28) View more	-	27 Jan 2026
				Placebo (Placebo)	ivdjpbmlch(xkmzovymnl) = uitortgmof hxijamkdip (mtlqdjaxkx, 1.18) View more
NCT05093933 (VICTOR \| MK-1242-035, CTgov)	Phase 3	Reduced ejection fraction co-occurrent and due to chronic heart failure \| Chronic heart failure	6,106	Vericiguat (Vericiguat)	gjebjhufqo = qywrkxehkl tralhykcpc (gakdiwbhbr, xzujuubhmw - wwjrlbjbcw) View more	-	19 Dec 2025
				Placebo (Placebo)	gjebjhufqo = mtetghfvkj tralhykcpc (gakdiwbhbr, squaerzzky - jbuifywfbu) View more
NCT06195930 (VELOCITY, Pubmed \| Eur J Heart Fail)	Phase 2	Heart Failure	106	Vericiguat 5 mg	wczxuuamvb(ukjgkprfwh) = yntagnrwfe nexlrqxvva (wombbbjppn )	Positive	01 Dec 2025
NCT06195930 (VELOCITY, CTgov)	Phase 2	Reduced ejection fraction co-occurrent and due to chronic heart failure \| Chronic heart failure	106	Vericiguat	igksspausm = qkyqxpdqjz wqsbvrhdqf (zjikkxzxaz, qraacaxgqe - jfdhibzczs) View more	-	25 Sep 2025
NCT05093933 (VICTOR, Company_Website \| Lancet) Manual	Phase 3	Heart failure with reduced ejection fraction	6,105	Vericiguat	izdmymzinr(uqwshncojg) = ihwqrxkxqy fdwaqndpde (meiffsfqoo ) View more	Negative	29 Aug 2025
				placebo	izdmymzinr(uqwshncojg) = fhjxhbbzwj fdwaqndpde (meiffsfqoo ) View more
NCT02861534 (VICTORIA, Pubmed \| J Card Fail)	Phase 3	Heart Failure GDF-15 \| NT-proBNP \| albumin ... View more	373	Vericiguat	xzhsufgkdu(oysvgzzvom): HR = 0.85 (95.0% CI, 0.77 - 0.94) View more	Positive	01 Aug 2025
				Placebo
VELOCITY (NEWS) Manual	Phase 2	Heart failure with mid range ejection fraction	106	维立西呱 5mg	ysuxdsddef(ymhmhrgxgm) = lvecwpbkmc wkiwavxlky (ddjgnnypiz ) Met	Positive	20 May 2025
ESC2024	Not Applicable	Heart Failure	-	Vericiguat	xoglsennqt(efvtthnzgc) = xkwdplvdke dnpebxukan (dtkrlcnfzj, 1.05)	-	13 May 2024
NCT02861534 (VICTORIA, ESC2024)	Phase 3	Heart Failure NTproBNP	200	Vericiguat	kborjkjpak(sdwrlxdcqb) = ulhtkzebuu jlyhpntwcd (tgzmswandk )	Positive	12 May 2024
ESC2024	Not Applicable	-	-	vericiguat (Women)	oaxknwshyd(malunuesox) = vmdwfbljxa jvlakgnxxs (qcinoidext ) View more	-	12 May 2024
				vericiguat (Men)	oaxknwshyd(malunuesox) = hjtbyaisky jvlakgnxxs (qcinoidext ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis